Studies have shown that G6PD mutations in patients with AML may lead to redox imbalance, which, in turn, affects tumor cell growth and drug resistance, especially in FLT3 inhibitor therapy, where G6PD-driven redox metabolism promotes the development of drug resistance [40,46]. This evidence concerns the gene FLT3 and acute myeloid leukemia.